Patent ID: 8586634

Claim:
A method of treating a GPCR-mediated disorder in a subject comprising administering to the subject identified as in need thereof a compound, wherein the GPCR-mediated disorder is selected from a neuropsychiatric disorder, a neurodegenerative disorder, a neurological disorder, a cardiovascular disorder, a gastrointestinal disorder, or a genito-urinary tract disorder; and the compound is: wherein, R 1 is independently H, NH 2 , NH(alkyl), N(alkyl) 2 ; R 2 is independently —(CH 2 )n-; Each n is independently 1 or 2; R 3 is independently H, OH, or halo; R 4 is independently H, OH, or halo; R 5 is alkyl or halo; R 6 is independently H or alkyl; R 7 independently H, N(alkyl) 2 ; the neuropsychiatric disorder is selected from the group consisting of obesity, addiction, anxiety, depression, schizophrenia, and sleep disorders; the neurodegenerative disorder is selected from the group consisting of Parkinson's Disease and Alzheimer's Disease; the neurological disorder is epilepsy; the cardiovascular disorder is hypertension; the gastrointestinal disorder is irritable bowel syndrome; and the genito-urinary tract disorder is bladder control.